GlobeNewsWire
18 Nov 2026, 12:50 UTC · 1h ago
Allarity Therapeutics Granted U.S. Patent for Stenoparib's Clinical Dosing Regimen, with Protection Into 2045
Impact · against what's priced in
Allarity Therapeutics gains significant structural valuation through a newly granted patent extending Stenoparib's exclusivity to 2045. The broad claim coverage across various solid tumors increases the asset's long-term appeal for licensing or M&A.
Scored by the NIS engine · methodology.





